Miacalcic (Calcitonin Salmon, Synthetic)

Synthetic salmon calcitonin binds to calcitonin receptors on osteoclasts, inhibiting their activity and reducing bone resorption. This decreases the release of calcium from bone into the bloodstream, leading to lower serum calcium levels. It also promotes renal calcium excretion, contributing to overall calcium balance.

The dosing regimen for Miacalcic is individualized by the prescribing healthcare professional based on the specific indication, patient characteristics, and response to therapy. The prescriber determines the appropriate dose, route (intramuscular, subcutaneous, or intravenous), and frequency, following local prescribing guidelines and product labeling.

The safety of synthetic salmon calcitonin in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit justifies any potential risk to the fetus or infant. Consultation with a healthcare provider is essential.

To place an order, submit an enquiry on the Miacalcic product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Compared with other agents such as bisphosphonates or denosumab, synthetic salmon calcitonin has a rapid onset of action in lowering serum calcium and is administered by injection, often used for short‑term management. It may be less potent for long‑term fracture risk reduction but offers an alternative when other therapies are contraindicated or not tolerated.

Miacalcic should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears cloudy or contains particles. Proper cold‑chain management is essential to maintain product stability.

Miacalcic is supplied as an injectable solution and may be given intramuscularly, subcutaneously, or intravenously, depending on the clinical indication and prescriber’s direction. Administration should be performed by a qualified healthcare professional using aseptic technique, and the dose is adjusted according to the patient’s response and monitoring results.

The most serious adverse reactions include severe hypocalcemia, anaphylactic or severe allergic responses, and marked hypotension that may require medical intervention. Patients should be monitored for signs of these events, especially during the initial dosing period, and treatment should be stopped immediately if a serious reaction occurs.

Miacalcic is contraindicated in individuals with known hypersensitivity to salmon calcitonin or any excipients in the formulation. Caution is advised for patients with severe renal impairment, uncontrolled hypertension, or a history of severe allergic reactions. It should also be avoided in patients where calcium lowering could be harmful unless closely supervised by a physician.